{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:40:51Z","timestamp":1790786451539,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.phrs.2017.12.021","type":"journal-article","created":{"date-parts":[[2017,12,25]],"date-time":"2017-12-25T10:10:39Z","timestamp":1514196639000},"page":"1-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"special_numbering":"C","title":["Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers"],"prefix":"10.1016","volume":"128","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdollah","family":"Sadeghi-Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2017.12.021_bib0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2017.12.021_bib0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2017.12.021_bib0015","first-page":"1519","article-title":"Human ret proto-oncogene mapped to chromosome 10q11.2","volume":"4","author":"Ishizaka","year":"1989","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2017.12.021_bib0020","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/381789a0","article-title":"GDNF signalling through the Ret receptor tyrosine kinase","volume":"381","author":"Durbee","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2017.12.021_bib0025","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.12.021_bib0030","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2017.12.021_bib0035","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.molcel.2014.01.015","article-title":"Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans","volume":"53","author":"Plaza-Menacho","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2017.12.021_bib0040","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.cellsig.2014.03.032","article-title":"Mechanisms of RET signaling in cancer: current and future implications for targeted therapy","volume":"26","author":"Plaza-Menacho","year":"2014","journal-title":"Cell. Signal."},{"key":"10.1016\/j.phrs.2017.12.021_bib0045","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.celrep.2016.11.061","article-title":"RET functions as a dual-specificity kinase that requires allosteric inputs from juxtamembrane elements","volume":"17","author":"Plaza-Menacho","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2017.12.021_bib0050","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1074\/jbc.271.10.5309","article-title":"Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities","volume":"271","author":"Liu","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0055","doi-asserted-by":"crossref","first-page":"33577","DOI":"10.1074\/jbc.M605604200","article-title":"Structure and chemical inhibition of the RET tyrosine kinase domain","volume":"281","author":"Knowles","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0060","doi-asserted-by":"crossref","first-page":"14213","DOI":"10.1074\/jbc.M312600200","article-title":"Identification of RET autophosphorylation sites by mass spectrometry","volume":"279","author":"Kawamoto","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0065","doi-asserted-by":"crossref","first-page":"35808","DOI":"10.1074\/jbc.M104968200","article-title":"Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site","volume":"276","author":"Anders","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2017.12.021_bib0075","series-title":"The MD Anderson Manual of Medical Oncology","first-page":"903","article-title":"Endocrine malignancies","author":"Kwatampora","year":"2016"},{"key":"10.1016\/j.phrs.2017.12.021_bib0080","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.12.021_bib0085","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel targets in non-small cell lung cancer: ROS1 and RET fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2017.12.021_bib0090","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nrc3612","article-title":"Tyrosine kinase gene rearrangements in epithelial malignancies","volume":"13","author":"Shaw","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2017.12.021_bib0095","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/cncr.28661","article-title":"RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma","volume":"120","author":"Krampitz","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2017.12.021_bib0100","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2017.12.021_bib0105","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2017.12.021_bib0110","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/367375a0","article-title":"A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma","volume":"367","author":"Hofstra","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2017.12.021_bib0115","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2017.12.021_bib0120","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","author":"Drilon","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2017.12.021_bib0125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","article-title":"PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas","volume":"60","author":"Grieco","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2017.12.021_bib0130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nm.2644","article-title":"KIF5B-RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2017.12.021_bib0135","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2017.12.021_bib0140","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2017.12.021_bib0145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0150","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6: The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2017.12.021_bib0155","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.12.021_bib0160","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.12.021_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0170","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/1568026617666170224121313","article-title":"Structure-based virtual screening approaches in kinase-directed drug discovery","volume":"17","author":"Bajusz","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0180","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos. Trans. R Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2017.12.021_bib0185","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","article-title":"Regulation of protein kinases; controlling activity through activation segment conformation","volume":"15","author":"Nolen","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2017.12.021_bib0190","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"ErbB\/HER protein-tyrosine kinases: structures and small molecule inhibitors","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2017.12.021_bib0200","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi971438n","article-title":"Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase","volume":"36","author":"Zhou","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2017.12.021_bib0205","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.12.021_bib0210","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.12.021_bib0215","first-page":"69","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"69","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0220","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2016.09.011","article-title":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms","volume":"113","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0225","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0230","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0240","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0245","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0250","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0255","doi-asserted-by":"crossref","first-page":"e1001690","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2017.12.021_bib0260","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1073\/pnas.94.8.3565","article-title":"Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates","volume":"94","author":"Shah","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.12.021_bib0265","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0270","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0275","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0280","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1535-7163.MCT-14-0274","article-title":"Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer","volume":"13","author":"Kodama","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2017.12.021_bib0285","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1021\/jm501464c","article-title":"Progress in discovery of KIF5B-RET kinase inhibitors for the treatment of non-small-cell lung cancer","volume":"58","author":"Song","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0290","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0295","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/med.21409","article-title":"Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview","volume":"37","author":"Fischer","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2017.12.021_bib0300","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/13543776.2017.1238073","article-title":"RET kinase inhibitors: a review of recent patents (2012\u20132015)","volume":"27","author":"Mologni","year":"2017","journal-title":"Expert Opin. Ther. Pat"},{"key":"10.1016\/j.phrs.2017.12.021_bib0305","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/14656566.2017.1340939","article-title":"Advances in small molecule therapy for treating metastatic thyroid cancer","volume":"18","author":"Krajewska","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2017.12.021_bib0310","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.phrs.2017.12.021_bib0315","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0022-2836(63)80091-1","article-title":"Allosteric proteins and cellular control systems","volume":"6","author":"Monod","year":"1963","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2017.12.021_bib0320","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the gatekeeper door: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0325","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.phrs.2017.12.021_bib0330","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2017.12.021_bib0335","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1021\/acs.jmedchem.5b02041","article-title":"Delineation of polypharmacology across the human structural kinome using a functional site interaction fingerprint approach","volume":"59","author":"Zhao","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0340","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0345","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00894-015-2708-z","article-title":"Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase","volume":"21","author":"Gao","year":"2015","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.phrs.2017.12.021_bib0350","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring: 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.12.021_bib0355","doi-asserted-by":"crossref","first-page":"10741","DOI":"10.1158\/0008-5472.CAN-06-3329","article-title":"Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B","volume":"66","author":"Gujral","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2017.12.021_bib0360","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1089\/thy.2013.0137","article-title":"In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer","volume":"23","author":"Bentzien","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.phrs.2017.12.021_bib0365","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1158\/1078-0432.CCR-16-1887","article-title":"Antitumor activity of RXDX-105 in multiple cancer types with RET rearrangements or mutations","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"27","key":"10.1016\/j.phrs.2017.12.021_bib0370","first-page":"3070","article-title":"Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening\u2013a report from the American Society of Clinical Oncology. J Clin Oncol 27:812-26. Erratum in","volume":"2009","author":"Winer","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"294","key":"10.1016\/j.phrs.2017.12.021_bib0375","doi-asserted-by":"crossref","first-page":"re6","DOI":"10.1126\/scisignal.2004652","article-title":"Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer","volume":"6","author":"Niederst","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.phrs.2017.12.021_bib0380","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/cb300610s","article-title":"Kinase drug discovery \u2212what's next in the field?","volume":"8","author":"Cohen","year":"2013","journal-title":"ACS Chem. Biol."},{"issue":"8","key":"10.1016\/j.phrs.2017.12.021_bib0385","doi-asserted-by":"crossref","first-page":"e0181585","DOI":"10.1371\/journal.pone.0181585","article-title":"Progress towards a public chemogenomic set for protein kinases and a call for contributions","volume":"12","author":"Drewry","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2017.12.021_bib0390","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817316651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817316651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T22:55:35Z","timestamp":1535151335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817316651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":78,"alternative-id":["S1043661817316651"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.12.021","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}